Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HUTCHMED (China) Limited ( (HK:0013) ) has issued an announcement.
HUTCHMED and Innovent Biologics have announced that their FRUSICA-2 Phase II/III study has met its primary endpoint for the combination treatment of fruquintinib and sintilimab in advanced renal cell carcinoma (RCC) in China. This development marks a significant advancement in RCC treatment, offering a promising new option for patients who have not responded adequately to previous therapies. The study’s positive results highlight the potential of this combination therapy to address unmet medical needs in the RCC patient population, reinforcing HUTCHMED’s commitment to advancing cancer treatments.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates primarily in China and collaborates with partners like Innovent Biologics to advance its drug pipeline.
YTD Price Performance: -1.70%
Average Trading Volume: 45,792
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.1B
For an in-depth examination of 0013 stock, go to TipRanks’ Stock Analysis page.